Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials

Clinical Drug Investigation
Adrian J B Brady

Abstract

The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease. Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although availa...Continue Reading

References

May 1, 1986·Clinical Pharmacology and Therapeutics·J P BussienH R Brunner
Aug 1, 1996·Clinical and Experimental Pharmacology & Physiology·P A FennessyG R Campbell
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Apr 30, 2003·Hypertension·Lorenzo GhiadoniAntonio Salvetti
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Jan 21, 2004·Hypertension·Michel E SafarGérard E Plante
Jul 28, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Ernesto L Schiffrin, Rhian M Touyz
Aug 11, 2004·European Heart Journal·José López-SendónUNKNOWN Task Force on ACE-inhibitors of the European Society of Cardiology
Oct 7, 2004·Current Medical Research and Opinion·Michel E Bertrand
Nov 27, 2004·BMJ : British Medical Journal·Subodh Verma, Marty Strauss
Feb 23, 2005·Expert Review of Cardiovascular Therapy·Roberto Ferrari
Aug 6, 2005·European Heart Journal·Paolo VerdecchiaGian Paolo Reboldi
Aug 27, 2005·Journal of Human Hypertension·B M Y CheungC R Kumana
Sep 27, 2005·BMJ : British Medical Journal·Michael A McDonaldRoss T Tsuyuki
Nov 5, 2005·Journal of Hypertension·Massimo VolpeBruno Trimarco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

© 2021 Meta ULC. All rights reserved